Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans.
about
Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactamsA critical review of the fluoroquinolones: focus on respiratory infectionsMutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosisActivity of gatifloxacin alone or in combination with pyrimethamine or gamma interferon against Toxoplasma gondiiStructure-activity relationships of quinolone agents against mycobacteria: effect of structural modifications at the 8 positionApplication of a method used to deconstruct a single dose pharmacokinetic profile from multiple dose data.Gatifloxacin: a new fluoroquinolone.Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecidActivities of gatifloxacin compared to those of seven other agents against anaerobic organisms.Pharmacodynamics of gatifloxacin in cerebrospinal fluid in experimental cephalosporin-resistant pneumococcal meningitisComparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters.Activity of gatifloxacin against Haemophilus influenzae and Moraxella catarrhalis, including susceptibility test development, E-test comparisons, and quality control guidelines for H. influenzae.Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study.Clinical pharmacology of gatifloxacin, a new fluoroquinolone.Pharmacodynamic evaluation of commonly prescribed oral antibiotics against respiratory bacterial pathogens.A review of clinical trials with fluoroquinolones with an emphasis on new agents.Ciprofloxacin dosage and emergence of resistance in human commensal bacteriaPharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection modelsAn update on community-acquired pneumonia in adults.Fluoroquinolone drug class update.In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp.The new fluoroquinolones: A critical reviewAmino acid substitutions at position 95 in GyrA can add fluoroquinolone resistance to Mycobacterium leprae.Population pharmacokinetic model for gatifloxacin in pediatric patients.Effects of probenecid and cimetidine on the pharmacokinetics of nemonoxacin in healthy Chinese volunteersEvaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.Competitive inhibition of renal tubular secretion of gemifloxacin by probenecid.In-vitro activity of gatifloxacin against Chlamydia trachomatis and Chlamydia pneumoniae.Analytical methods for determination of new fluoroquinolones in biological matrices and pharmaceutical formulations by liquid chromatography: a review.Fluoroquinolone disposition: identification of the contribution of renal secretory and reabsorptive drug transporters.Human organic cation transporters 1 (SLC22A1), 2 (SLC22A2), and 3 (SLC22A3) as disposition pathways for fluoroquinolone antimicrobials.Biotransformation and bioactivation reactions of alicyclic amines in drug molecules.Pharmacokinetics of intravenous finafloxacin in healthy volunteers.Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.Postantibiotic effects of gatifloxacin against gram-positive and -negative organisms.Concentrations of gatifloxacin in plasma and urine and penetration into prostatic and seminal fluid, ejaculate, and sperm cells after single oral administrations of 400 milligrams to volunteers.Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract.Gatifloxacin efficacy in treatment of experimental methicillin-sensitive Staphylococcus aureus-induced osteomyelitis in rabbits.Gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis: safety, efficacy and patient perspective.In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus.
P2860
Q24631021-2A82FF90-C33C-4A14-94F5-F71B2CD92657Q28215446-6F65B39A-1888-42B1-B1E4-8AA7931C3E5CQ28344614-8B1D5EC8-DCE4-417D-9CAF-DDCE2C59BF92Q28345231-8C6BED70-B7B7-47A2-8BD0-6C91E5611B51Q28379263-9022849B-6A4C-4954-8F83-0897FC7ECD88Q30909557-264DEB1E-5EC0-42FD-9DED-4E1614B59343Q31522155-2ACC7D35-871D-4C69-BF2A-98ECD53629EFQ33668223-410F3375-2C71-43D8-B182-F78EDA8DEDC5Q33697562-EBDD281E-7AB2-4B1E-8A80-FA0823F28A5AQ33699541-BA81E41F-A1D3-448D-807E-F0E48E0CF632Q33895157-A1D8AB43-C376-42E9-84DA-C4084A794E1EQ33961044-B1D75DBC-5612-4BEE-AE3E-94FE33ED2906Q33982775-5EAFC67E-6E39-4959-9367-0FBF14F6E4ACQ34030783-660FA51C-3D71-4902-91BD-314B8432CEBEQ34057534-08F6AC4E-65B3-43E2-88C2-818183E2903AQ34074724-F7C0B831-591E-4D46-9FCB-5E38D12DC0F8Q34104262-790AB1A9-657D-46EC-AF6E-388FC15569E1Q34108149-6483486B-4E5F-4542-98A2-0FF2D4074D8DQ34110799-65BC5850-8C61-4B19-A786-729F4BAE7EB4Q34231182-E8236BE2-BFA0-4805-82A0-47610D9378D2Q35136707-3C0CE291-7FEC-4E54-A2DE-B7A36B1D703CQ35649595-D005E221-2860-40D4-AAFA-8BDC5D79FA14Q35689265-C136D7A2-1A2C-478D-AF4B-D0576C8D9CD7Q35758967-7D9D865B-6C11-4368-8DB3-E6124BCA97F9Q36498735-65F49C3A-41CE-4BAA-877D-5C836CECF7A8Q37124090-66B8118E-E15D-48A1-9FEE-82FCF7E42727Q37333151-AB6B903A-F008-4D6E-8CE5-3F8D08CA0BBCQ37877336-FE16B419-BE94-4A2F-BEFB-FFF5B6429F4FQ37982661-CDB5C953-0EF9-4374-B77E-9980F65624CEQ37995676-7BF15C93-3492-43E5-8E42-19746A0F973AQ38094882-05C015EB-E1C4-40EF-9F21-0A798DE550C7Q38218540-1E42D43C-F24D-4F6A-BD2F-C874061557A5Q38636236-0B5A2C9C-4DB2-4932-9349-6CF0D1A160C8Q39470007-95532C2E-59BD-4F7F-A2BD-059227D1FF84Q39472095-AD45C5D7-A068-451A-AA52-48FEA73478E7Q39476038-9E21C7C7-D555-4DF6-9E08-6CC0395E377FQ39559460-32882A8A-9171-4383-B835-84F68B59F20CQ39651061-D622FAA3-E123-4438-B3EE-892906C7A56FQ39675169-EC1CE558-82C6-415C-8881-9F6A515E2B7DQ39746394-894F9313-3AAE-404E-9E28-E35224DC13C7
P2860
Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Single- and multiple-dose phar ...... -methoxy quinolone, in humans.
@en
Single- and multiple-dose phar ...... -methoxy quinolone, in humans.
@nl
type
label
Single- and multiple-dose phar ...... -methoxy quinolone, in humans.
@en
Single- and multiple-dose phar ...... -methoxy quinolone, in humans.
@nl
prefLabel
Single- and multiple-dose phar ...... -methoxy quinolone, in humans.
@en
Single- and multiple-dose phar ...... -methoxy quinolone, in humans.
@nl
P2093
P2860
P356
P1476
Single- and multiple-dose phar ...... -methoxy quinolone, in humans.
@en
P2093
H Kusajima
M Nakashima
P2860
P304
P356
10.1128/AAC.39.12.2635
P407
P577
1995-12-01T00:00:00Z